Division: Pharmacy Policy	Subject: State of Florida's Agency for Health Care Administration's Prior Authorization Criteria
Original Development Date: Original Effective Date: Revision Date:	May 29, 2015 March 10, 2020, March 31, 2020, October 15, 2021

JADENU® (deferasirox)

TYPE OF IRON OVERLOAD	LENGTH OF AUTHORIZATION
Transfusional/Non-Transfusional	Up to 1 year

REVIEW CRITERIA:

Transfusional Iron Overload initiation of Therapy:

1. Patient must be ≥2 years of age on the date of request for Jadenu with chronic iron overload due to blood transfusions.
2. Documentation of iron overload related to anemia found in patient's medical conditions, progress notes, and/or discharge notes.
3. Documentation in medical records (e.g., progress notes, discharge notes. . .) of a recent history of frequent blood transfusions that has resulted in chronic iron overload.
4. Documentation in medical records (*eg. progress notes, discharge notes*. . .) of failure of Exjade (after a minimum of 3 months of therapy) as demonstrated by serum ferritin must be consistently >1000 mcg/L despite maximization of Exjade dosage of 40mg/kg/day. (Lab results submitted should be dated within the past month.)
5. Starting dose is 14 mg/kg/day. Calculate dose to the nearest whole tablet (90 mg, 180 mg, or 360 mg).

Transfusional Iron Overload continuation of therapy:

1. Ferritin levels must be >500mcg/L.
2. Dose must not exceed 28mg/kg/day.
3. Calculate dose to the nearest whole tablet (90 mg, 180 mg, or 360 mg).

Non-Transfusional Iron Overload initiation of therapy:

1. Patient must be ≥10 years of age on the date of request for Jadenu with non-transfusion-dependent thalassemia.
2. Documentation of iron overload related to anemia found in patient's medical conditions, progress notes, and/or discharge notes.
3. Serum ferritin and liver iron concentration (LIC) must have been measured within 30 days of initiation (copy lab results must be submitted).

Division: Pharmacy Policy	Subject: State of Florida's Agency for Health Care Administration's Prior Authorization Criteria
Original Development Date: Original Effective Date: Revision Date:	May 29, 2015 March 10, 2020, March 31, 2020, October 15, 2021

4. Documentation in medical records (*eg. progress notes, discharge notes. . .*) of failure of Exjade (after a minimum of 3 months of therapy) as demonstrated by serum ferritin must be consistently >300 mcg/L despite maximization of Exjade dosage of 40mg/kg/day. (Lab results submitted should be dated within the past month.)
5. Liver iron concentration (LIC) must be ≥5 mg Fe/g dried weight (dw)
6. Starting dose is 7mg/kg/day. Calculate dose to the nearest whole tablet (90 mg, 180 mg, or 360 mg).

Non-Transfusional Iron Overload continuation of therapy:

1. Serum ferritin levels must be >300mcg/L.
2. Liver iron concentration (LIC) must be ≥3 mg Fe/g dw.
3. Dose must not exceed: 14mg/kg/day.
4. Calculate dose to the nearest whole tablet (90 mg, 180 mg, or 360 mg).